DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sangamo Therapeutics
Sangamo Therapeutics
SANGAMO THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter)
Medicines in Development -- Cell Therapy and Gene Therapy
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
Sangamo Therapeutics Reports First Quarter 2019 Financial Results
Family Conference Dec
Post-Event Summary
Sangamo Biosciences Presents New Data from in Vivo Protein Replacement Platform Programs for MPS I and MPS II at the 12Th Annual Worldsymposium™ Meeting
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results
Sangamo Therapeutics Announces Presentations at 2019 Annual Meeting of the American Society of Gene & Cell Therapy
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
Sangamo Announces Publication in Molecular Therapy of Preclinical Study Data from MPS II in Vivo Genome Editing Program
Sangamo Announces Upcoming Clinical Data Presentations at Worldsymposium 2019
Sangamo Therapeutics, Inc. (SGMO)
SANGAMO THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter) ______
Gene Therapy Clinical Pipeline
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D
Biogen Inc. 2020 Annual Report
Top View
I, Virginie Hivert
Sangamo Announces $8 Million CIRM Grant for ST-400 -- a Gene-Edited Cell Therapy Candidate -- to Treat Transfusion-Dependent Beta-Thalassemia
Sangamo Biosciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS I
Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
A Gene-Edited Cell Therapy Candidate -- to Treat Beta-Thalassemia
Sangamo Therapeutics Annual Report 2020
Sangamo Biosciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
Sponsorship Prospectus Cell & Gene Meeting on the Mesa October 3-5, 2018 La Jolla, CA